Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Pharmacol Exp Ther
2010 Dec 01;3353:614-21. doi: 10.1124/jpet.110.174144.
Show Gene links
Show Anatomy links
A novel family of negative and positive allosteric modulators of NMDA receptors.
Costa BM, Irvine MW, Fang G, Eaves RJ, Mayo-Martin MB, Skifter DA, Jane DE, Monaghan DT.
???displayArticle.abstract???
The N-methyl-D-aspartate (NMDA) receptor family regulates various central nervous system functions, such as synaptic plasticity. However, hypo- or hyperactivation of NMDA receptors is critically involved in many neurological and psychiatric conditions, such as pain, stroke, epilepsy, neurodegeneration, schizophrenia, and depression. Consequently, subtype-selective positive and negative modulators of NMDA receptor function have many potential therapeutic applications not addressed by currently available compounds. We have identified allosteric modulators with several novel patterns of NMDA receptor subtype selectivity that have a novel mechanism of action. In a series of carboxylated naphthalene and phenanthrene derivatives, compounds were identified that selectively potentiate responses at GluN1/GluN2A [e.g., 9-iodophenanthrene-3-carboxylic acid (UBP512)]; GluN1/GluN2A and GluN1/GluN2B [9-cyclopropylphenanthrene-3-carboxylic acid (UBP710)]; GluN1/GluN2D [3,5-dihydroxynaphthalene-2-carboxylic acid (UBP551)]; or GluN1/GluN2C and GluN1/GluN2D receptors [6-, 7-, 8-, and 9-nitro isomers of naphth[1,2-c][1,2,5]oxadiazole-5-sulfonic acid (NSC339614)] and have no effect or inhibit responses at the other NMDA receptors. Selective inhibition was also observed; UBP512 inhibits only GluN1/GluN2C and GluN1/GluN2D receptors, whereas 6-bromo-2-oxo-2H-chromene-3-carboxylic acid (UBP608) inhibits GluN1/GluN2A receptors with a 23-fold selectivity compared with GluN1/GluN2D receptors. The actions of these compounds were not competitive with the agonists L-glutamate or glycine and were not voltage-dependent. Whereas the N-terminal regulatory domain was not necessary for activity of either potentiators or inhibitors, segment 2 of the agonist ligand-binding domain was important for potentiating activity, whereas subtype-specific inhibitory activity was dependent upon segment 1. In terms of chemical structure, activity profile, and mechanism of action, these modulators represent a new class of pharmacological agents for the study of NMDA receptor subtype function and provide novel lead compounds for a variety of neurological disorders.
Ahmed,
Piracetam defines a new binding site for allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors.
2010, Pubmed
Ahmed,
Piracetam defines a new binding site for allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors.
2010,
Pubmed Balannik,
Molecular mechanism of AMPA receptor noncompetitive antagonism.
2005,
Pubmed
,
Xenbase Baron,
NR2D-containing NMDA receptors mediate tissue plasminogen activator-promoted neuronal excitotoxicity.
2010,
Pubmed Brickley,
NR2B and NR2D subunits coassemble in cerebellar Golgi cells to form a distinct NMDA receptor subtype restricted to extrasynaptic sites.
2003,
Pubmed Buller,
The molecular basis of NMDA receptor subtypes: native receptor diversity is predicted by subunit composition.
1994,
Pubmed
,
Xenbase Chen,
Differential roles of NMDA receptor subtypes in ischemic neuronal cell death and ischemic tolerance.
2008,
Pubmed Cull-Candy,
NMDA receptor subunits: diversity, development and disease.
2001,
Pubmed Davis,
Effects of D-cycloserine on extinction: translation from preclinical to clinical work.
2006,
Pubmed DeRidder,
Traumatic mechanical injury to the hippocampus in vitro causes regional caspase-3 and calpain activation that is influenced by NMDA receptor subunit composition.
2006,
Pubmed Dingledine,
The glutamate receptor ion channels.
1999,
Pubmed Gielen,
Mechanism of differential control of NMDA receptor activity by NR2 subunits.
2009,
Pubmed Hardingham,
The Yin and Yang of NMDA receptor signalling.
2003,
Pubmed Hizue,
Involvement of N-methyl-D-aspartate-type glutamate receptor epsilon1 and epsilon4 subunits in tonic inflammatory pain and neuropathic pain.
2005,
Pubmed Hrabetova,
Distinct NMDA receptor subpopulations contribute to long-term potentiation and long-term depression induction.
2000,
Pubmed
,
Xenbase Kalia,
NMDA receptors in clinical neurology: excitatory times ahead.
2008,
Pubmed Khosravani,
Prion protein attenuates excitotoxicity by inhibiting NMDA receptors.
2008,
Pubmed Koutsilieri,
Excitotoxicity and new antiglutamatergic strategies in Parkinson's disease and Alzheimer's disease.
2007,
Pubmed Laube,
Evidence for a tetrameric structure of recombinant NMDA receptors.
1998,
Pubmed
,
Xenbase Laurén,
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers.
2009,
Pubmed Lindsley,
Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.
2006,
Pubmed Lozovaya,
Extrasynaptic NR2B and NR2D subunits of NMDA receptors shape 'superslow' afterburst EPSC in rat hippocampus.
2004,
Pubmed
,
Xenbase Madry,
Supralinear potentiation of NR1/NR3A excitatory glycine receptors by Zn2+ and NR1 antagonist.
2008,
Pubmed
,
Xenbase Momiyama,
Distinct synaptic and extrasynaptic NMDA receptors identified in dorsal horn neurones of the adult rat spinal cord.
2000,
Pubmed Monaghan,
The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system.
1989,
Pubmed Monyer,
Developmental and regional expression in the rat brain and functional properties of four NMDA receptors.
1994,
Pubmed Monyer,
Heteromeric NMDA receptors: molecular and functional distinction of subtypes.
1992,
Pubmed O'Collins,
1,026 experimental treatments in acute stroke.
2006,
Pubmed Paoletti,
Molecular organization of a zinc binding n-terminal modulatory domain in a NMDA receptor subunit.
2000,
Pubmed
,
Xenbase Papadia,
Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses.
2008,
Pubmed Rachline,
The micromolar zinc-binding domain on the NMDA receptor subunit NR2B.
2005,
Pubmed
,
Xenbase Salter,
NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury.
2005,
Pubmed Sanacora,
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.
2008,
Pubmed Terasaki,
Activation of NR2A receptors induces ischemic tolerance through CREB signaling.
2010,
Pubmed Thomas,
Synaptic and extrasynaptic NMDA receptor NR2 subunits in cultured hippocampal neurons.
2006,
Pubmed Tovar,
The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro.
1999,
Pubmed Villmann,
On the hypes and falls in neuroprotection: targeting the NMDA receptor.
2007,
Pubmed von Engelhardt,
Excitotoxicity in vitro by NR2A- and NR2B-containing NMDA receptors.
2007,
Pubmed Watkins,
Pharmacology of receptors for excitatory amino acids.
1981,
Pubmed Yuan,
Control of NMDA receptor function by the NR2 subunit amino-terminal domain.
2009,
Pubmed
,
Xenbase
